China, UAE Make Big Progress In Ensuring Safe Blood Donation
China and the United Arab Emirates (UAE) have made impressive strides in tackling the risk of contamination from unsafe blood by reaching close to 100% voluntary blood donation, said WHO today. Their efforts to increase their safe blood base will be promoted as models for other countries to follow on the occasion of World Blood Donor Day.
Celgene Withdraws European Union EU Marketing Authorization Application For Lenalidomide In Deletion-5Q Myelodysplastic Syndromes
Celgene International Sarl (NASDAQ: CELG) announced that, following discussions with the European Medicines Agency (EMEA) and the EMEA's Committee for Medicinal Products for Human use (CHMP), it has withdrawn its Marketing Authorization Application (MAA) for Lenalidomide - Celgene Europe (lenalid.
Novo Nordisk And Neose Announce Completion Of Initial Phase 1 Clinical Trial Of NN7128 Long-Acting Factor VIIa
Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (Nasdaq GM:NTEC) announced that Novo Nordisk has completed the initial Phase 1 clinical trial with NN7128 (GlycoPEGylated Factor VIIa), a long-acting version of NovoSeven Coagulation Factor FVIIa (Recombinant) administered intravenously.
US Department Of Defense Recommends Soldiers Carry WoundStat trade; For Life-Threatening Bleeding
TraumaCure Inc. announced that the DOD Joint Committee on Tactical Combat Casualty Care (CoTCCC) has recommended that U.S. soldiers from all services carry the company's hemostatic agent, WoundStat™ . The CoTCCC based its recommendations upon the results of extensive studies conducted by both the Army's Institute for Surgical Research (ISR) and the Naval Medical Research Center (NMRC).
Research Shows VASER Ultrasound Assisted Lipoplasty Patients Experience Significantly Lower Blood Loss
Findings from a comparative analysis study of blood loss during lipoplasty procedures shows VASER ultrasound-assisted lipoplasty causes significantly less blood loss when compared to traditional tumescent lipoplasty. Results of the study were presented at the annual meeting of the American Society for Aesthetic Plastic Surgery held the first week of May at the San Diego Convention Center.
Risk Of Contamination From Unsafe Blood - China And United Arab Emirates Make Rapid Progress
China and the United Arab Emirates (UAE) have made impressive strides in tackling the risk of contamination from unsafe blood by reaching close to 100% voluntary blood donation, said the World Health Organization today. Their efforts to increase their safe blood base will be promoted as models for other countries to follow on the occasion of World Blood Donor Day, on 14 June.
New Molecular Insight Into Amboebic Dysentery
In the June 15th issue of G&D, Dr. Sinisa Urban (Johns Hopkins University School of Medicine) and colleagues reveal a potential role for the rhomboid enzyme, EhROM1, in the pathogenesis of the enteric protozoan parasite, E. histolytica. This discovery posits EhROM1 as a prospective target in the treatment of amoebic dysentery, which affects 1/10th of the global population (~500 million people) and represents the second most common disease in the world.
Hemophilia - Extended Half-Life Recombinant VIIa Leads To Longer Biologic Activity
New data presented at Hemophilia 2008 seen as another step to single dosing regimen of one injection per bleeding event for hemophilia patients with inhibitors CSL Behring presented results of a pre-clinical study that not only demonstrates the feasibility of genetically fusing factor VIIa to human albumin, but that this therapeutic protein with a prolonged half-life can lead to a longer biologic effect.
AdvanDx Submits Yeast Traffic Light PNA FISH TM For FDA 510 k Clearance For Detection Of Candida Species In Positive Blood Cultures
AdvanDx announced the FDA 510(k) submission of Yeast Traffic Light PNA FISH(TM) for detection of Candida yeast species from positive blood cultures. Yeast Traffic Light(TM) is the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH(TM) diagnostics platform that provides rapid identification of bloodstream pathogens in hours instead of days.
Boehringer Ingelheim Gets First Approval Within EU For Actilyse R 2mg To Treat Catheter Dysfunction Caused By Thrombotic Occlusion
Boehringer Ingelheim announced the first approval for Actilyse (alteplase) 2mg within the European Union, which was communicated by the reference member state Germany after successful completion of a mutual recognition procedure. The new indication is for the thrombolytic treatment of occluded central venous access devices (CVAD), including those used for haemodialysis.